Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03485-7, published online 5 February 2025.
In the version of the article initially published, the title read “…phase 3 CEPHEUS study” rather than “…phase 3 CEPHEUS trial” and has now been corrected in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Usmani, S.Z., Facon, T., Hungria, V. et al. Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Nat Med 31, 1366 (2025). https://doi.org/10.1038/s41591-025-03581-2
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41591-025-03581-2
